How Duke is Improving Outcomes and Navigating Reimbursement 

For patients with heart failure with reduced ejection fraction (HFrEF), Barostim is a device therapy that works with drug therapies to target the neurohormonal pathways responsible for heart failure progression and symptoms. In this on demand webinar, presented by Cardiovascular Business and CVRx, Marat Fudim, MD, MHS and Joanna Kipnes, MD, MS, FHM from Duke University, along with Bonnie Handke, RN, MBA from CVRx, share Duke University’s best practices, patient outcomes, and real world experience in incorporating Barostim into their heart failure program.

By watching this webinar, you’ll learn about:

• The value of integrating Barostim into a comprehensive heart failure program
• How drug therapies and Barostim target the neurohormonal pathways responsible for heart failure progression – and how to identify patients earlier
• Timelines for starting a program and the key roles the physician champion needs to play
• Patient outcomes and new data on reducing hospitalizations
• How CVRx supports programs in getting started and ensuring appropriate reimbursement
• How facilities can actively navigate prior authorization and remove barriers to payment 

Dr. Marat Fudim and Dr. Joanna Kipnes are paid consultants of CVRx.